physostigmine has been researched along with Diabetes Mellitus, Type 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia, CC; Hognason, K; McArdle, JJ; Potian, JG; Routh, VH; Souayah, N; Sultatos, LG; Thyagarajan, B | 1 |
| Caffarri, G; Capretti, L; Chiodera, P; Coiro, V; Colla, R; Vescovi, PP; Volpi, R | 1 |
1 trial(s) available for physostigmine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Dopaminergic and cholinergic control of arginine-vasopressin secretion in type I diabetic men.
Topics: Acetylcholine; Adult; Apomorphine; Arginine Vasopressin; Blood Pressure; Diabetes Mellitus, Type 1; Dopamine; Humans; Male; Physostigmine | 1995 |
1 other study(ies) available for physostigmine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Neuropathies; GPI-Linked Proteins; Hyperglycemia; Male; Mice; Motor Endplate; Muscle Weakness; Neuromuscular Junction Diseases; Physostigmine | 2012 |